CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $22,243,304 | +23.8% | 699,695 | -5.0% | 0.04% | -2.5% |
Q1 2023 | $17,963,748 | -46.5% | 736,521 | -30.8% | 0.04% | -69.2% |
Q4 2022 | $33,571,208 | +1.7% | 1,064,401 | -8.9% | 0.13% | +21.5% |
Q3 2022 | $33,024,000 | +3.1% | 1,168,596 | -3.5% | 0.11% | +24.4% |
Q2 2022 | $32,018,000 | -46.1% | 1,210,979 | -28.7% | 0.09% | -27.7% |
Q1 2022 | $59,426,000 | -4.0% | 1,697,376 | -11.1% | 0.12% | +3.5% |
Q4 2021 | $61,891,000 | -32.9% | 1,909,035 | -38.9% | 0.12% | -26.3% |
Q3 2021 | $92,230,000 | +36.0% | 3,126,435 | +18.1% | 0.16% | +56.0% |
Q2 2021 | $67,801,000 | +182.2% | 2,646,435 | +51.2% | 0.10% | +177.8% |
Q1 2021 | $24,028,000 | -17.2% | 1,750,000 | 0.0% | 0.04% | -23.4% |
Q4 2020 | $29,015,000 | – | 1,750,000 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,913,749,385 | 28.70% |
Perceptive Advisors | 10,088,385 | $320,709,759 | 9.28% |
Affinity Asset Advisors, LLC | 550,000 | $17,484,500 | 6.11% |
Finepoint Capital LP | 492,545 | $15,658,006 | 5.42% |
Paradigm Biocapital Advisors LP | 1,868,946 | $59,413,793 | 4.59% |
BOONE CAPITAL MANAGEMENT LLC | 300,000 | $9,537,000 | 3.42% |
Rock Springs Capital Management LP | 2,513,916 | $79,917,390 | 1.90% |
Artal Group S.A. | 1,638,858 | $52,099 | 1.62% |
Frazier Life Sciences Management, L.P. | 393,000 | $12,493,470 | 0.75% |
Avidity Partners Management LP | 501,200 | $15,933,148 | 0.56% |